The global fibrin market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of the market is attributed to factors such as increasing demand for fibrin in various applications and rising awareness about its benefits among end users. The global human fibrinogen concentrate market is expected to grow at a CAGR of 4.8% during the forecast period, from 2021 to 2030. The growth of this segment can be attributed to factors such as increasing demand for human fibrinogen concentrate in various applications and rising awareness about its benefits among end users. The global animal fibrinogen concentrate market is expected to grow at a CAGR of 6% during the forecast period, from 2021-2030 due to factors such as increasing demand for animal fibrinogen concentrate in various applications and rising awareness about its benefits among end users.
Some Of The Growth Factors Of This Market:
- Fibrin has been used in various surgical procedures such as hernia repair and organ transplantation.
- Fibrin is also used in wound healing applications.
- Increasing incidence of cardiovascular diseases will drive the demand for fibrin.
- Increasing awareness about the benefits of using fibrin will fuel its growth.
Industry Growth Insights published a new data on “Fibrin Market”. The research report is titled “Fibrin Market research by Types (Human Fibrinogen Concentrate, Animal Fibrinogen Concentrate), By Applications (Trauma patients, Cardiovascular surgery patients, PPH patients, Plastic surgery patients, Others), By Players/Companies CSL Behring, Baxter, Johnson & Johnson (Ethicon), LFB Group, ProFibrix BV, Shanghai RAAS Blood Products, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological Engineering, Harbin Pacific Biopharmaceutical, GREEN CROSS, Shanghai XinXing Medical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Fibrin Market Research Report
By Type
Human Fibrinogen Concentrate, Animal Fibrinogen Concentrate
By Application
Trauma patients, Cardiovascular surgery patients, PPH patients, Plastic surgery patients, Others
By Companies
CSL Behring, Baxter, Johnson & Johnson (Ethicon), LFB Group, ProFibrix BV, Shanghai RAAS Blood Products, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological Engineering, Harbin Pacific Biopharmaceutical, GREEN CROSS, Shanghai XinXing Medical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Fibrin Market Report Segments:
The global Fibrin market is segmented on the basis of:
Types
Human Fibrinogen Concentrate, Animal Fibrinogen Concentrate
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Trauma patients, Cardiovascular surgery patients, PPH patients, Plastic surgery patients, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CSL Behring
- Baxter
- Johnson & Johnson (Ethicon)
- LFB Group
- ProFibrix BV
- Shanghai RAAS Blood Products
- Jiangxi Boya Bio-Pharmaceutical
- Hualan Biological Engineering
- Harbin Pacific Biopharmaceutical
- GREEN CROSS
- Shanghai XinXing Medical
Highlights of The Fibrin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Human Fibrinogen Concentrate
- Animal Fibrinogen Concentrate
- By Application:
- Trauma patients
- Cardiovascular surgery patients
- PPH patients
- Plastic surgery patients
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fibrin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fibrin is a protein that helps to form clots.
Some of the major companies in the fibrin market are CSL Behring, Baxter, Johnson & Johnson (Ethicon), LFB Group, ProFibrix BV, Shanghai RAAS Blood Products, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological Engineering, Harbin Pacific Biopharmaceutical, GREEN CROSS, Shanghai XinXing Medical.
The fibrin market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Fibrin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Fibrin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Fibrin Market - Supply Chain
4.5. Global Fibrin Market Forecast
4.5.1. Fibrin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Fibrin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Fibrin Market Absolute $ Opportunity
5. Global Fibrin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Fibrin Market Size and Volume Forecast by Type
5.3.1. Human Fibrinogen Concentrate
5.3.2. Animal Fibrinogen Concentrate
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Fibrin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Fibrin Market Size and Volume Forecast by Application
6.3.1. Trauma patients
6.3.2. Cardiovascular surgery patients
6.3.3. PPH patients
6.3.4. Plastic surgery patients
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Fibrin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Fibrin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Fibrin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Fibrin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Fibrin Demand Share Forecast, 2019-2026
9. North America Fibrin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Fibrin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Fibrin Market Size and Volume Forecast by Application
9.4.1. Trauma patients
9.4.2. Cardiovascular surgery patients
9.4.3. PPH patients
9.4.4. Plastic surgery patients
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Fibrin Market Size and Volume Forecast by Type
9.7.1. Human Fibrinogen Concentrate
9.7.2. Animal Fibrinogen Concentrate
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Fibrin Demand Share Forecast, 2019-2026
10. Latin America Fibrin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Fibrin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Fibrin Market Size and Volume Forecast by Application
10.4.1. Trauma patients
10.4.2. Cardiovascular surgery patients
10.4.3. PPH patients
10.4.4. Plastic surgery patients
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Fibrin Market Size and Volume Forecast by Type
10.7.1. Human Fibrinogen Concentrate
10.7.2. Animal Fibrinogen Concentrate
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Fibrin Demand Share Forecast, 2019-2026
11. Europe Fibrin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Fibrin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Fibrin Market Size and Volume Forecast by Application
11.4.1. Trauma patients
11.4.2. Cardiovascular surgery patients
11.4.3. PPH patients
11.4.4. Plastic surgery patients
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Fibrin Market Size and Volume Forecast by Type
11.7.1. Human Fibrinogen Concentrate
11.7.2. Animal Fibrinogen Concentrate
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Fibrin Demand Share, 2019-2026
12. Asia Pacific Fibrin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Fibrin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Fibrin Market Size and Volume Forecast by Application
12.4.1. Trauma patients
12.4.2. Cardiovascular surgery patients
12.4.3. PPH patients
12.4.4. Plastic surgery patients
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Fibrin Market Size and Volume Forecast by Type
12.7.1. Human Fibrinogen Concentrate
12.7.2. Animal Fibrinogen Concentrate
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Fibrin Demand Share, 2019-2026
13. Middle East & Africa Fibrin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Fibrin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Fibrin Market Size and Volume Forecast by Application
13.4.1. Trauma patients
13.4.2. Cardiovascular surgery patients
13.4.3. PPH patients
13.4.4. Plastic surgery patients
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Fibrin Market Size and Volume Forecast by Type
13.7.1. Human Fibrinogen Concentrate
13.7.2. Animal Fibrinogen Concentrate
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Fibrin Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Fibrin Market: Market Share Analysis
14.2. Fibrin Distributors and Customers
14.3. Fibrin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. CSL Behring
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Baxter
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Johnson & Johnson (Ethicon)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. LFB Group
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ProFibrix BV
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Shanghai RAAS Blood Products
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Jiangxi Boya Bio-Pharmaceutical
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Hualan Biological Engineering
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Harbin Pacific Biopharmaceutical
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. GREEN CROSS
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Shanghai XinXing Medical
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook